Fe-S Clusters Emerging as Targets of Therapeutic Drugs

Table 1

Therapeutic drugs interacting with Fe-S clusters.

Drug	Therapeutical property	Therapeutic indication	Fe-S cluster-containing target	Mechanism	Reference
Hydroxyurea	Antiproliferative	Sickle cell disease, leukemia, polycythemia vera, other cancers	Leu1	ROS-mediated	[79]
Primaquine	Antiparasite	Malaria	Rli1, aconitase	Fe-S cluster interaction and ROS-mediated	[88]
MAD-28 (cluvenone derivative)	Antiproliferative	Cancer	MitoNEET, NAF-1	Fe-S cluster destabilization	[57]
Cluvenone	Proapoptotic	Acute lymphoblastic leukemia	MitoNEET, NAF-1	Fe-S cluster stabilization	[56, 57]
Pioglitazone (thiazolidinedione family)	Antidiabetes insulin sensitizer	Diabetes	MitoNEET, NAF-1	Fe-S cluster stabilization	[67, 70, 71]
‘882	Antimicrobial		SUF machinery	Binding to Fe-S cluster biogenesis machinery	[80]
Antibiotics	Antimicrobial	Bacterial infections		ROS-mediated (still a matter of debate)	[35, 41–43, 47]
β-Phenethyl isothiocyanate (PEITC)	Antiproliferative	Leukemia	NADH dehydrogenase 3 (respiratory complex I)	ROS-mediated	[48]
BC1	Antiangiogenic, antitumor	Ehrlich carcinoma		ROS-mediated	[49]